STOCK TITAN

Voyager Therapeutics Inc - VYGR STOCK NEWS

Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.

Voyager Therapeutics Inc (VYGR) is a leader in developing gene therapies for central nervous system disorders through its proprietary TRACER™ platform. This page provides investors and researchers with essential updates on clinical developments, strategic partnerships, and scientific breakthroughs in AAV-based treatments.

Access curated press releases and news articles covering key milestones in Voyager’s pipeline, including therapies for Parkinson’s disease, ALS, and Friedreich’s ataxia. Stay informed about advancements in blood-brain barrier penetration technology and preclinical validation studies across multiple species.

Our repository features updates on clinical trial progress, regulatory developments, and collaborative research initiatives. Discover analysis of vector optimization achievements and manufacturing scalability efforts critical to gene therapy commercialization.

Bookmark this page for consolidated access to verified information about Voyager’s neurogenetic innovations. Check regularly for objective reporting on therapeutic candidate progression and industry leadership in CNS-targeted gene delivery solutions.

Rhea-AI Summary
Voyager Therapeutics reported Q3 2023 financial and operating results, highlighting the initiation of GLP toxicology studies for their anti-tau antibody VY-TAU01 and progress in their SOD1 ALS gene therapy program. The company expects to file an IND for VY-TAU01 in 1H 2024 and select a development candidate for the SOD1 ALS program by the end of the year. Voyager also mentioned multiple opportunities for INDs in 2025 across their pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
-
Rhea-AI Summary
Voyager Therapeutics, a biotechnology company, will report its Q3 2023 financial and operating results on November 6, 2023. A conference call and webcast will be held to review the results. Telephone participants can register in advance to receive a confirmation email with details on how to join the call. The webcast will be available on the Voyager website, and a replay will be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
-
Rhea-AI Summary
Voyager Therapeutics CEO to present at Chardan conference on Oct 2
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
Rhea-AI Summary
Voyager Therapeutics grants non-qualified stock options and restricted stock units to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
-
Rhea-AI Summary
Voyager Therapeutics to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
-
Rhea-AI Summary
Voyager Therapeutics to participate in Fireside Chat at Canaccord Genuity Annual Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
Voyager Therapeutics Inc

Nasdaq:VYGR

VYGR Rankings

VYGR Stock Data

174.45M
46.01M
17%
63.9%
4.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
LEXINGTON